abacavir 600 MG Lamivudine 300 MG Oral Tablet

1 INDICATIONS AND USAGE Abacavir and lamivudine tablets, a combination of abacavir and lamivudine, both nucleoside analogue HIV-1 reverse transcriptase inhibitors, are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. ( 1 ) Abacavir and lamivudine tablets, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.

Zydus Pharmaceuticals (USA) Inc.

FDA Reported Adverse Reactions
`[1] toxicity to various agents` `[2] drug ineffective` `[3] nausea` `[4] completed suicide` `[5] headache` `[6] drug abuse` `[7] pain` `[8] fatigue` `[9] pulmonary embolism` `[10] off label use`

4 years ago

OVAL YELLOW 1049

16 HOW SUPPLIED/STORAGE AND HANDLING

ABACAVIR AND LAMIVUDINE tablets, USP contain 600 mg of abacavir (equivalent to 702.00 mg abacavir sulfate, USP) and 300 mg of lamivudine, USP.

ABACAVIR AND LAMIVUDINE Tablets USP, 600 mg/300 mg are light yellow to yellow, modified capsule shaped, coated tablets, debossed with "1049" on one side and plain on the other side and are supplied as: NDC 70710-1049-3 in bottle of 30 tablets with child-resistant closure NDC 70710-1049-9 in bottle of 90 tablets with child-resistant closure Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

More pills like OVAL 1049

Related Pills

Doxepin Hydrochloride Doxepin Hydrochloride 10 MG Oral Capsule

Mylan Institutional Inc.

LAMOTRIGINE lamotrigine 200 MG Oral Tablet

PD-Rx Pharmaceuticals, Inc.

DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site